Navigation Links
Ovarian cancers detected early may be less aggressive, questioning effectiveness of screening
Date:3/24/2009

DURHAM, N.C. -- The biology of ovarian cancers discovered at an early stage may render them slower growing and less likely to spread than more aggressive cancers, which typically are discovered in an advanced stage, according to a study led by investigators in the Duke Comprehensive Cancer Center. This finding has implications for the question of whether screening for ovarian cancer could save lives.

"Our study showed that the ovarian cancers currently detected at an early stage have gene expression profiles that correlate with favorable outcome, rather than being representative of the entire spectrum of disease aggressiveness," said Andrew Berchuck, M.D., a gynecologic oncologist at Duke and lead investigator on this study. "This highlights the potential challenges of developing a screening test for this disease, because earlier detection of aggressive cases is essential if screening is to reduce ovarian cancer deaths."

The results of this study and the implications for screening as an approach to decreasing mortality parallel the challenges seen in lung cancer and prostate cancer. In those cancers, while screening approaches based on radiological imaging and/or blood markers detect cancers, it remains unclear whether cancer-related deaths are prevented because screening preferentially detects more benign cancers that are much less likely to be fatal, Berchuck said.

"While these results could be seen as discouraging, it must be remembered that this information is an important piece of the ovarian cancer puzzle, and data like these that increase our understanding of the disease hopefully will eventually lead to breakthroughs in prevention, early detection and treatment of this deadly disease," Berchuck said.

Although there is currently no approved ovarian cancer screening test for the general population, the CA125 blood test and transvaginal ultrasound imaging currently are being evaluated in clinical trials.

The
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
2. Combo Screening Doesnt Spot Early Ovarian Cancer
3. Early Detection Remains Key in Updated NCCN Guidelines for Ovarian Cancer
4. Combo of Tests Might Spot Ovarian Cancer Early
5. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
6. Fertility Drugs Do Not Increase Ovarian Cancer Risk
7. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
8. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
9. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
10. Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer
11. Obesity Linked to Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
...ct. 1 Sunnylife Global, Inc.,(Pink Sheets: SNYL) ...ns,and financial public relations services. At a ... quality,healthcare management in China and build ...We are thrilled to have been retained to represent...
...J., Oct. 1 Wedgewood Pharmacy and Midwest,Veterin...gency agreement,through which Midwest will represe...000 veterinary clinics in 27 states. The relations...gewood,s compounding services will,be offered to v...
...Oct. 1 In honor of Hispanic Heritage,Month in the...speakers,worldwide, the International Hyperhidrosi...version of its popular patient education brochure.... speak at,the 21st World Congress of Dermatology o...
...chultz Investigates the "Social Brain" in Children...ILADELPHIA, Oct. 1 An internationally,prominent e...ts with,autism, Robert T. Schultz, Ph.D., is joini... Most recently the director of the Yale Developmen...
..., Oct. 1 Merlyn Medical has announced,receipt of ...id warmer that,requires neither battery nor electr...2007 EMS Expo in Orlando, FL, October 11-13 and th...ation vehicles, field use, rescue, or other applic...
...est Distributors and Pharmacy Chains to Carry RESP...evice, NEW YORK and MAROOCHYDORE, Australia, Oct....hat its RESPeRATE(R) hypertension,treatment device... marketing and distribution partner, High Tech,Hea...
Other Medicine News:Health News:Sunnylife Global Retains The Blaine Group For Investor Relations, Financial Public Relations 2Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 2Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 3Health News:In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish 2Health News:Brain Imaging Expert Recruited to Study Autism at The Children's Hospital of Philadelphia 2Health News:Brain Imaging Expert Recruited to Study Autism at The Children's Hospital of Philadelphia 3Health News:Merlyn Medical Announces FDA Approval for FlexWarmer in a Joint Agreement with Elltec and Suzuken 2Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 2Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 3Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 4
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Researchers Propose Improved Cervical Cancer Screening 57807 1Researchers Propose Improved Cervical Cancer Screening 57807 2Nanoresearchers challenge dogma in protein transportation in cells 10001 1Nanoresearchers challenge dogma in protein transportation in cells 10001 2American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 1American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 2American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 3American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 4American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 5
...ounces a $50,000 Grant from,Verizon to help preven...HILADELPHIA, Feb. 7 The Center for Injury,Researc...ladelphia is,pleased to announce a $50,000 grant r...children after an injury. Researchers at the Cente...lies to develop effective,screening tools and inte...
...ologies, Inc. (Nasdaq: EMIS ) announced today tha... concept that absorption of oral vitamin,B12 using...s 15-30 times,greater than with the same dose of o...igen(R) technology is the basis of the company,s u...es and pharmaceutical compounds., "This data demo...
Other Medicine Technology:Helping Families Cope After an Injury 2Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology 2Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology 3
Gibco Penicillin-Streptomycin liquid
Gibco Antibiotic-Antimycotic (100X), liquid
Gentamicin, 50 mg/ml
GENTAMICIN SULFATE, 1000X
Medicine Products: